Clinical Trials Directory

Trials / Completed

CompletedNCT02402595

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Avanir Pharmaceuticals · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.

Detailed description

A Phase 1, single-center, randomized, double-blind, double-dummy drug interaction study.

Conditions

Interventions

TypeNameDescription
DRUGAVP-923
DRUGAVP-786
DRUGItraconazole

Timeline

Start date
2015-03-01
Primary completion
2015-07-01
Completion
2015-07-01
First posted
2015-03-30
Last updated
2017-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02402595. Inclusion in this directory is not an endorsement.

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts (NCT02402595) · Clinical Trials Directory